business

AbbVie Nears $11 Billion Acquisition of Apogee; Regenxbio Advances Gene Therapy

22 Haziran 2026Bloomberg

AbbVie is reportedly finalizing an $11 billion acquisition of Apogee Therapeutics, which has led to a significant rise in Apogee's stock prices. Meanwhile, Regenxbio's shares are also gaining traction following the FDA's alignment on the next steps for its gene therapy drug, Navsunli, which is aimed at treating Muco…
In contrast, SpaceX's stock is experiencing a decline after its recent IPO performance.
The pharmaceutical industry is currently witnessing a wave of mergers and acquisitions as companies aim to enhance their research and development capabilities. The FDA's recent support for Regenxbio's gene therapy underscores the regulatory body's increasing openness to innovative treatments, which is critical for c…
The impending acquisition of Apogee by AbbVie highlights the ongoing trend of large pharmaceutical companies seeking to bolster their portfolios through strategic acquisitions. This move not only reflects AbbVie's commitment to expanding its presence in the inflammatory disease market but also signals confidence in…

NewsAI özeti

This article is for informational purposes only and does not constitute financial advice.

Tam teknik rapor ve canlı veriler için yayıncının web sitesini ziyaret edin.

Her yerde okuyun. iOS ve Android için ödüllü uygulamalarımızı indirin.